SSG
RVMD icon

Summit Securities Group’s Revolution Medicines RVMD Stock Holding History

Summit Securities Group’s Portfolio RVMD Stock Details RVMD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-1,500
Closed -$43K – 831
2023
Q4 		$43K Buy
+1,500
New +$36K ﹤0.01% 410

Other funds holding RVMD

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
DGM
Darwin Global Management St. Helier, Jersey $3.76B AUM 342.13% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
NI
Nextech Invest Zurich, Switzerland $2.11B AUM 413.84% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return

Summit Securities Group's RVMD Position: Q2 2026 in Review

Summit Securities Group sold out of Revolution Medicines (RVMD) in Q2 2026, closing a stake of 400 shares — an estimated $38.9K sold.

Summit Securities Group first reported a position in RVMD in Q4 2023 and held it in 3 quarters. The position peaked at $703K in Q4 2023. 691 funds tracked by Wall St. Rank hold RVMD as of Q2 2026.

  • Summit Securities Group reported no remaining Revolution Medicines position as of Q2 2026 after selling out during the quarter.
  • Summit Securities Group sold 400 Revolution Medicines shares in Q2 2026, an estimated $38.9K.
  • Summit Securities Group first reported a position in Revolution Medicines in Q4 2023 and held it in 3 quarters.
  • Summit Securities Group's Revolution Medicines position peaked at $703K in Q4 2023.
  • 691 funds tracked by Wall St. Rank held Revolution Medicines as of Q2 2026.

Based on Summit Securities Group's 13F filing for Q2 2026, filed 3 Aug 2026.